This item requires a subscription to Endocrine-Related Cancer.
Full Text (PDF)
To view this item, select one of the options below:
SfE Members Sign In
- Society for Endocrinology members, please sign in via SfE website to access the journal online.
ESE Members Sign In
- European Society of Endocrinology members, please sign in via ESE website to access the journal online.
Sign In
Purchase Short-Term Access
- Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00.
- Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Sign Up
- Subscribe to the Journal - Subscribe to the print and/or online journal.
Newsletter Sign-up
Sign up to journal email newsletters containing the latest news and content. When you submit your details you will receive
an email where you can confirm which journal newsletters you would like to receive. If you do not receive this email, please
check your junk mail.
This Article
- Show PDF in full window
- AbstractFree
- Figures Only
- Full Text
- Full Text (PDF)
- Supplementary Data
-
All Versions of this Article:
- ERC-17-0306v1
- 25/1/1 most recent
Article Metrics
Services
Citing Articles
Google Scholar
PubMed
Related Content
Most
-
Viewed
- Association of Hashimoto's thyroiditis with thyroid cancer
- Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors
- Advances in adrenal tumors 2018
- Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma
- Bone metastases from differentiated thyroid carcinoma
-
Cited
- Fibroblast growth factors, their receptors and signaling
- The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification
- BRAF mutation in thyroid cancer
- mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
- Discovery of a novel Raf kinase inhibitor
